Consortium gets $7.2 million contract renewal to promote phase II clinical trials

October 28, 2011

TAMPA, Fla. -- The National Cancer Institute recently awarded $7.2 million for the competitive renewal of the Southeast Phase 2 Consortium (SEP2C), led by Moffitt Cancer Center's Daniel Sullivan, M.D., executive vice president and associate center director for Clinical Investigations. The renewal is through September 2016.

The SEP2C enrolls patients to phase II clinical trials and some phase I trials across six member sites. Moffitt is the lead site for the large contract that is awarded through the NCI's N01 research and development contract mechanism. The first year is projected to provide nearly $1.5 million.

The other member sites are UNC Lineberger Comprehensive Cancer; Vanderbilt-Ingram Cancer Center; Winship Cancer Institute of Emory University; VCU Massey Cancer Center; and the Cancer Institute of New Jersey.

Patient accrual at Moffitt will be focused on the following cancers: acute myeloid leukemia, breast, colorectal, lung, myelodysplastic syndrome, melanoma, multiple myeloma, non-Hodgkin's lymphoma, ovarian and sarcoma, as well as on immunotherapy and novel phase I trials. The consortium provides full management of the clinical trials including initiation, assessing eligibility, recruitment, evaluation of toxicity and response, auditing, follow-up, and analysis of results.
-end-
About Moffitt Cancer Center

Follow Moffitt on Facebook: http://www.facebook.com/MoffittCancerCenter

Follow Moffitt on Twitter: @MoffittNews

Follow Moffitt on YouTube: MoffittNews

Located in Tampa, Florida, Moffitt Cancer Center is an NCI Comprehensive Cancer Center - a designation that recognizes Moffitt's excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 14 affiliates in Florida, one in Georgia, one in Pennsylvania and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country's leading cancer centers, and is listed in U.S. News & World Report as one of "America's Best Hospitals" for cancer. Moffitt marks a very important anniversary in 2011 - 25 years committed to one mission: to contribute to the prevention and cure of cancer.

H. Lee Moffitt Cancer Center & Research Institute

Related Multiple Myeloma Articles from Brightsurf:

Penn Study supports use of radiation before CAR therapy for multiple myeloma
Administering radiation therapy to multiple myeloma patients waiting for CAR T cells to be manufactured was found to be safe and undisruptive to CAR T therapy.

New multiple myeloma therapy shows promise in preclinical study
A new alpha-radioimmunotherapy, 212Pb-anti-CD38, has proven effective in preventing tumor growth and increasing survival in multiple myeloma tumor-bearing mice, according to new research published in the July issue of The Journal of Nuclear Medicine.

A safer cell therapy harnesses patient T cells to fight multiple myeloma
A treatment for multiple myeloma that harnesses the body's cancer-fighting T cells was safe in humans and showed preliminary signs of effectiveness, according to a clinical trial involving 23 patients with relapsed or treatment-resistant disease.

Colorado tool, My-DST, may pick best multiple myeloma treatment
Response of liquid biopsies to approved drugs can help show resistance, predict response.

Case study: Treating COVID-19 in a patient with multiple myeloma
A case study of a patient in Wuhan, China, suggests that the immunosuppressant tocilizumab may be an effective COVID-19 treatment for very ill patients who also have multiple myeloma and other blood cancers.

New drug could reverse treatment resistance in advanced multiple myeloma
Researchers at the VU University Medical Center in the Netherlands have tested a new drug in patient samples and mice with multiple myeloma and discovered that it was effective even in advanced disease -- a point when many patients currently run out of options.

Single gene cluster loss may contribute to initiation/progression of multiple myeloma
The loss of one copy of the miR15a/miR16-1 gene cluster promoted initiation and progression of multiple myeloma in mice.

New CAR-T target yields promising results for multiple myeloma
In research published today in the journal Nature Communications, Utah-based scientists describe a novel way to treat cancers using chimeric antigen receptor (CAR) T cell therapy.

BCMA-targeted immunotherapy can lead to durable responses in multiple myeloma
An experimental, off-the-shelf immunotherapy that combines a targeted antibody and chemotherapy can lead to potentially durable responses in multiple myeloma patients whose disease has relapsed or is resistant to other standard therapies.

Study finds racial disparities in treatment of multiple myeloma patients
Among patients with multiple myeloma, African-Americans and Hispanics start treatment with a novel therapy significantly later than white patients, according to a new study published today in Blood Advances.

Read More: Multiple Myeloma News and Multiple Myeloma Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.